PTO/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

Substitut	fe for form 1449/PTO			Complete if Known			
DEATE	ge 10/10/11/1443/1/10			Application Number	10/589,116		
INFORMATION DISCLOSURE				Filing Date	August 11, 2006		
STATEMENT BY APPLICANT				First Named Inventor	SOREQ, Hermona et al.		
	// to	.4		Art Unit			
	(Use as many she	ets as n	ecessary)	Examiner Name			
Sheet	1	of	8	Attorney Docket Number	7640-X06-063		

	_	NON PATENT LITERATURE DOCUMENTS	
Initials* No.1 the item (book, magazine, journal, serial, symposium, catalog		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AA	ABO, T. and KAWAMURA, T., Ther. Apher., 2002, pp.348-357, vol.6.	
	AB	ABRAMSON, N. and MELTON, B., Am. Fam. Physician, 2000, pp.2053-2060., vol.62.	
	AC	BASSER, R.L. et al., Blood, 2002, pp.2599-2602, vol.99.	
	AD	BASSINI, A. et al., Blood, 1999, pp.1178-1188, vol.93.	
	AE	BIRIKH, K.R. et al, RNA Society, 1997, pp.429-437, vol.3.	
	AF	BOROVIKOVA, L.V. et al., Nature, 2000, pp.458-462, vol.405.	
	AG	BRENNER et al., FASEB J, 2003, pp.214-22, vol.17(2).	
	АН	BUSSLINGER, M., Ann. Rev. Immunol., 2004, pp.55-79, vol.22.	
	Al	CHAN, R.Y.Y. et al., J. Biol. Chem., 1998, pp.9727-9733, vol.273.	
	ΑJ	CRAIG, W. et al., Br. J. Haematol, 1994, pp.24-30, vol.88.	

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DONT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO			C required to respond to a compositor	Complete if Known
Oubstitu			3 1	Application Number	10/589,116
INF	ORMATION	DIS	CLOSURE	Filing Date	Feb 10,2005
STA	TEMENT B	Y A	PPLICANT	First Named Inventor	SOREQ, Hermona et al.
		_		Art Unit	
	(Use as many she	ets as n	iecessary)	Examiner Name	
Sheet	2	of	8	Attorney Docket Number	7640-X06-063

		NON PATENT LITERATURE DOCUMENTS	
Examiner Cite Initials* No.		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AK	DELGADO, I. et al., Gynecol. Obstet. Invest., 1994, pp.227-235, vol.38.	
	AL	DEUTSCH, V. et al., Exp. Hematol., 2002, pp.1153-1161, vol.30.	
	АМ	ERB, C. et al., J. Neurochem., 2001, pp.638-646, vol.77.	
	AN	FLORES-FLORES, C. et al., J. Neural Transm., 2002, pp.165-179, vol.62(supp).	
	АО	GAINSFORD, T. et al., Blood, 2000, pp.528-534, vol.95.	
	AP	GRISARU, D. et al., Mol. Cell Biol., 1999, pp.788-795, vol.19.	
	AQ	GRISARU, D. et al., Molecular Medicine, 2001, pp.93-105, vol.7.	
	AR	GUENECHEA, G. et al., Blood, 1999, pp.1097-1105, vol.93.	
	AS	HANADA and YOSHIMURA, Cytokine Growth Factor Rev., 2002, pp.413-421, vol.13.	
	АТ	HELLSTROM-LINDAHL, E. and NORDBERG, A., J. Neuroimmunol., 1996, pp.139-144, vol.68.	

_	 	
Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO		ct of 1995, no persons ar	Complete if Known		
Japsuta	te 10/10/11/ 1443/F10		•	Application Number	10/589,116	
INF	ORMATION	DÏS	CLOSURE	Filing Date	August 11, 2006	
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	SOREQ, Hermona et al.	
	//		,	Art Unit		
(Use as many sheets as necessary)				Examiner Name		
Sheet	3	of	8	Attorney Docket Number	7640-X06-063	

-		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	AU	ISHIBASHI, T. et al., Proc. Natl. Acad. Sci. U.S.A., 1989, pp.5953-5957, vol.86.	
	AV	JACKSON, C.W., Blood, 1973, pp.413-421, vol.42.	
	AW	JOHNSSON, B. et al., Anal. Biochem., 1991,pp.268-77, vol.198.	
	AX	KANAMARU, S. et al, Stem Cells, 2000, pp.190-195, vol.18.	
	AY	KASER, A. et al., Blood, 2001, pp.2720-2725, vol.98.	
	AZ	KAWASHIMA, K. and FUJI, T., Pharmacol Ther., 2000, pp.29-48, vol.86.	
	ВА	KIECOLT-GLASER, J.K. et al., Proc. Natl. Acad. Sci. U.S.A., 2003, pp.9090-9095, vol.100.	
	ВВ	KUTER, D.J., Transfusion, 2002, pp.279-283, vol.42.	
	вс	LAGASSE, E. and WEISSMAN, I.L., J. Immunol. Methods, 1996, pp.139-150, vol.197.	
	BD	LEV-LEHMAN, E. et al., Blood, 1997, pp.3644-3653, vol.89.	

Examiner	Date
Signature	Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO			e required to respond to a collection	Complete if Known		
Gubsiiu	te 101 101111 1443/F 10		·	Application Number	10/589,116		
INF	ORMATION	DIS	CLOSURE	Filing Date	August 11, 2006		
STA	TEMENT E	BY A	PPLICANT	First Named Inventor	SOREQ, Hermona et al.		
				Art Unit			
	(Use as many she	ets as n	ecessary)	Examiner Name			
Sheet	4	of	8	Attorney Docket Number	7640-X06-063		

		NON PATENT LITERATURE DOCUMENTS	_
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
•	BE	LI, K. et al., Br. J. Haematol., 1999, pp.178-185, vol.104.	
	BF	LI, Y. et al., J. Neurosci., 2000, pp.149-155, vol.20.	
	BG	MARCHISIO, M. et al., Anat. Rec., 1999, pp.7-14, vol.255.	
	вн	MASTORAKOS, G. and ILIAS, I., Ann. NY Acad. Sci., 2000, pp.95-106, vol.900.	
	ВІ	MILLER, G.E. et al., Health Psychol., 2002, pp.531-41, vol.21.	
	BJ	MITA, Y. et al., Eur. J. Pharmacol., 1996, pp.121-127, vol.297.	
	BK .	NAGATA, Y. et al., Thromb. Haemost., 1997, pp.808-814, vol.77.	
	BL	NAKASHIMA, K. et al., Semin Hematol., 1998, pp.210-221, vol.35.	
	ВМ	NITSCHE, A. et al., Haematologica, 2001, pp.693-699, vol.86.	
	BN	OSHEVSKI, S. et al., Biochem. Biophys. Res. Commun., 1999, pp.603-609, vol.263.	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information unless it contains a valid OMB control number.

	te for form 1449/PTO			Complete if Known			
Substitu	te for form 1449/P10			Application Number	10/589, 116		
INF	ORMATION	DIS	CLOSURE	Filing Date	August 11, 2006		
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	SOREQ, Hermona et al.		
				Art Unit			
	(Use as many she	ets as n	ecessary)	Examiner Name			
Sheet	5	of	8	Attorney Docket Number	7640-X06-063		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	во	PERRY, C. et al., Neoplasia, 2004, pp.279-86, vol.6(3).	
	ВР	PICK, M. et al., Br. J. Haematol., 1998, pp.639-650, vol.103.	
	BQ	PICK, M. et al., Ann. NY Acad. Sci., 2004, pp.85-95, vol.1018.	
	BR	PICK, M. et al., Exp. Hematol., 2002, p.1079, vol.30.	
	BS	PORCELLINI, A. et al., Int. J. Cell Cloning, 1983, pp.92-104, vol.1.	
	вт	RACKE, F.K. et al., J. Biol. Chem., 2001, pp.522-528, vol.276.	
	BU	REIZENSTEIN, P., Br. J. Haematol., 1979, pp.329-334, vol.43.	
-	BV	ROJNUCKARIN, P. et al., Blood, 2001, pp.154-161, vol.97.	
	BW	ROJNUCKARIN, P. et al., J. Biol. Chem., 2001, pp.41014-41022, vol.276.	
	вх	SKLAN, E.H. et al., Proc. Natl. Acad. Sci. U.S.A., 2004, pp.5512-5517, vol.101(15).	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

Un	der the Danenwork Bed	luction A	of 1995, no persons a	U.S. Patent	and Trademark Office; U.S. DEPARTMENT OF Confinencial of information unless it contains a valid OMB conf	OMMERCE rol number.
Substitute for form 1449/PTO				o required to respond to a concessor	Complete if Known	
Jubstitu	te 101 101111 1443/F10		lç	Application Number	10/589,116	
INF	ORMATION	DIS	CLOSURE	Filing Date	August 11, 2006	
STATEMENT BY APPLICANT				First Named Inventor	SOREQ, Hermona et al.	
				Art Unit		
(Use as many sheets as necessary)			ecessary)	Examiner Name		
Sheet	6	of	8 .	Attorney Docket Number	7640-X06-063	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BY	SOREQ, H. and SEIDMAN, S., Nat. Rev. Neurosci., 2001, pp.294-302, vol.2.	
	BZ	STERNFELD, M. et al., J. Neurosci., 1998, pp.1240-1249, vol.18.	
	CA	STERNFELD, M. et al., J. Physiol. Paris, 1998, pp.249-255, vol.92.	
	СВ	STERNFELD, M. et al., Proc. Natl. Acad. Sci. U.S.A., 2000, pp.8647-8652, vol.97.	
	СС	STOWE, R. P. et al., J. Leukoc. Biol., 1999, pp.179-186, vol.65.	
	CD	SZELENYI et al., Immunol. Letter, 1987, pp.49-54, vol.16.	
	CE	SZELENYI et al., Br. J. Haematol., 1982, pp.241-5, vol.50.	
	CF	TAVASSOLI, M., Blood Cells, 1991, pp.269-281, vol.17.	
	CG	TERAMURA, M. et al., Cancer Chemother. Pharmacol., 1996, pp.S99-102, vol.38(supp).	
	СН	TOFT, P. et al., Apmis, 1994, pp.43-48, vol.102.	

Examiner	Date	
Signature	 Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO	Complete if Known			
Substitute for form 1449/FTO	Application Number	10/589,116		
INFORMATION DISCLOSURE	Filing Date	August 11, 2006		
STATEMENT BY APPLICANT	First Named Inventor	SOREQ, Hermona et al.		
	Art Unit			
(Use as many sheets as necessary)	Examiner Name			
Sheet 7 of 8	Attorney Docket Number	7640-X06-063		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	СІ	TOPILKO and CAILLOU, Blood, 1985, pp.891-5, vol.66.	
	C1	TRACEY, K.J., Nature, 2002, pp.853-9, vol.420.	
	ск	TUIMALA, R. et al., Br. J. Obstret. Gynecol., 1976, pp.707-710, vol.83.	
	CL	WANAHITA, A. et al., Clin. Infect. Dis.,2002, pp.1585-1592, vol.34.	
	СМ	WANG, H. et al., Nature, 2003, pp.384-388, vol.421.	
	CN	WILSON et al., J. Am. Geriatr. Soc., 2002, pp.2041-2056, vol.50.	
	со	XU, Z. and WEISS, A., Nat. Immunol., 2002, pp.764-71, vol.3.	
·	СР	ZAHOREC, R., Bratisl. Lek. Listy., 2001, pp.5-14, vol.102.	
	CQ	ZHANG, X.J. et al., Cell Death Differ., 2002, pp.790-800, vol.9.	
	CR	DEUTSCH, V. et al., Blood, 2001, p. 73a, vol91 (11 - part1).	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	te for form 1449/PTO			complete if Known		
Cubball	10 10 10 11 1440 10			Application Number	10/589,116	
INF	ORMATION	DIS	CLOSURE	Filing Date	August 11, 2006	
STATEMENT BY APPLICANT				First Named Inventor	SOREQ, Hermona et al.	
	(lles so many short	-4		Art Unit		
(Use as many sheets as necessary)				Examiner Name		
Sheet	8	of	8	Attorney Docket Number	7640-X06-063	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	cs	International Search Report for PCT/IL05/000185	
	ст	International Prelim Report on Patentability for PCT/IL05/000185	
		·	

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.